...
首页> 外文期刊>Platelets >A single (investigator)-blind randomised control trial comparing the effects of quinapril and nifedipine on platelet function in patients with mild to moderate hypertension.
【24h】

A single (investigator)-blind randomised control trial comparing the effects of quinapril and nifedipine on platelet function in patients with mild to moderate hypertension.

机译:一项单项(研究者)盲人随机对照试验,比较了奎纳普利和硝苯地平对轻度至中度高血压患者血小板功能的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

The effect of quinapril and nifedipine on platelet aggregation, vascular endothelial function and coagulation system activity, was compared in a parallel-group, investigator-blind study carried out on patients with mild to moderate hypertension but no other diseases or receiving medication which might affect platelet function, vascular endothelium or coagulation. Forty patients (two groups of 20 patients each) and 20 control subjects were recruited. Patients were randomised to receive either quinapril or nifedipine retard and the dose escalated to control hypertension. Platelet aggregation studies were assessed serially and beta-thromboglobulin, angiotensin-converting enzyme (ACE), von Willebrand factor (vWF) coagulation factors VIIIc, XII and fibrinogen were measured at the beginning and end of the 12-week period. Blood pressure was adequately controlled in all patients in both groups. Platelet function was impaired in certain parameters (slope of the reaction with ADP and collagen and maximum aggregation with collagen) in the patient group compared to controls before treatment and this improved in patients on quinapril but not on nifedipine; likewise beta-thromboglobulin was higher in the patient group and fell significantly in the quinapril group but not those on nifedipine. Measurements of endothelial function and coagulation were normal before treatment and showed no alteration during the study, except in the expected fall in plasma ACE in the quinapril group. The results indicate that the ACE inhibitor, quinapril, has a beneficial effect on platelet function unlike the calcium channel blocker, nifedipine.
机译:在针对轻度至中度高血压但没有其他可能影响血小板的疾病或接受药物治疗的平行小组,研究者盲法研究中比较了奎尼普利和硝苯地平对血小板聚集,血管内皮功能和凝血系统活性的影响功能,血管内皮或凝血。招募了40位患者(两组,每组20位患者)和20位对照对象。患者被随机分配接受喹那普利或硝苯地平延缓治疗,剂量逐步增加以控制高血压。连续评估血小板凝集研究,并在12周周期的开始和结束时测量β-血栓球蛋白,血管紧张素转化酶(ACE),血管性血友病因子(vWF)凝血因子VIIIc,XII和纤维蛋白原。两组所有患者的血压均得到适当控制。与治疗前相比,患者组的某些参数(与ADP和胶原蛋白的反应斜率和与胶原蛋白的最大聚集)的某些参数会损害血小板功能,在喹那普利而非硝苯地平患者中血小板功能得到改善。同样,患者组中的β-血栓球蛋白较高,而奎那普利组中的β-血红蛋白水平显着下降,但硝苯地平组的β-血栓球蛋白则不明显。治疗前内皮功能和凝血功能的测量正常,研究期间无变化,除了喹那普利组血浆ACE的预期下降。结果表明,与钙通道阻滞剂硝苯地平不同,ACE抑制剂奎那普利对血小板功能具有有益作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号